795pa Prognostic Model for Predicting Radiographic Progression- Free Survival (rpfs) in Metastatic Castrate-resistant Prostate Cancer Men Treated with Second-line Chemotherapy.

S. Halabi1, H. Zhou1, E.J. Small2, N.C. Solomon1, A.J. Armstrong3, L. Shen4, S. Oudard5, O. Sartor6, J.S. de Bono7 Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA Medical Oncology, Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, NC, USA Biostatistics, Sanofi, Bridewater, NJ, USA Medical Oncology Service, Hopital European George Pompidou, Paris, FRANCE Department of Medicine: Section of Hematology & Medical Oncology and Department of Urology, Tulane Cancer Center, New Orleans, LA, USA Medical Oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research ICR, Sutton, UK